Form 4: IGM Biosciences CEO Sells Shares to Cover Tax Obligations

IGM Biosciences CEO, Mary Beth Harler, sold 1,708 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Mary Beth Harler, CEO of IGM Biosciences, sold 1,708 shares of common stock on December 16, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted average price of $7.48, with individual trades ranging from $7.00 to $7.84.
• Following the transaction, Ms. Harler directly owns 347,032 shares of IGM Biosciences common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction related to executive compensation and does not indicate any positive or negative sentiment.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Executive stock sales to cover tax obligations are a common practice across the biotechnology industry.
• Many companies use restricted stock units as part of their compensation packages, leading to similar sales by executives at other firms.
• The sale by Ms. Harler is not unusual in the context of executive compensation practices.

Stakeholder Impact

• The sale of shares by the CEO may have a minor impact on the stock price, but it is not expected to be significant.

Key Dates

Keywords

IGM Biosciences, stock sale, insider trading, Form 4, Mary Beth Harler, CEO, tax obligations, restricted stock units